OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes
Min Zhuo, Julie M. Paik, Deborah J. Wexler, et al.
American Journal of Kidney Diseases (2021) Vol. 79, Iss. 6, pp. 858-867.e1
Open Access | Times Cited: 51
Min Zhuo, Julie M. Paik, Deborah J. Wexler, et al.
American Journal of Kidney Diseases (2021) Vol. 79, Iss. 6, pp. 858-867.e1
Open Access | Times Cited: 51
Showing 1-25 of 51 citing articles:
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis
Arnaud D. Kazé, Min Zhuo, Seoyoung C. Kim, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 91
Arnaud D. Kazé, Min Zhuo, Seoyoung C. Kim, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 91
Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study
Che‐Yuan Wu, Carina Iskander, Christa Wang, et al.
Diabetes Care (2022) Vol. 46, Iss. 2, pp. 297-304
Open Access | Times Cited: 76
Che‐Yuan Wu, Carina Iskander, Christa Wang, et al.
Diabetes Care (2022) Vol. 46, Iss. 2, pp. 297-304
Open Access | Times Cited: 76
Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels
Elvira D’Andrea, Deborah J. Wexler, Seoyoung C. Kim, et al.
JAMA Internal Medicine (2023) Vol. 183, Iss. 3, pp. 242-242
Open Access | Times Cited: 54
Elvira D’Andrea, Deborah J. Wexler, Seoyoung C. Kim, et al.
JAMA Internal Medicine (2023) Vol. 183, Iss. 3, pp. 242-242
Open Access | Times Cited: 54
SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
Maria Elena Lunati, Vincenzo Cimino, Alessandra Gandolfi, et al.
Pharmacological Research (2022) Vol. 183, pp. 106396-106396
Closed Access | Times Cited: 39
Maria Elena Lunati, Vincenzo Cimino, Alessandra Gandolfi, et al.
Pharmacological Research (2022) Vol. 183, pp. 106396-106396
Closed Access | Times Cited: 39
Acute kidney injury in diabetes mellitus: Epidemiology, diagnostic, and therapeutic concepts
Yuan Gui, Zachary Palanza, Haiyan Fu, et al.
The FASEB Journal (2023) Vol. 37, Iss. 4
Open Access | Times Cited: 24
Yuan Gui, Zachary Palanza, Haiyan Fu, et al.
The FASEB Journal (2023) Vol. 37, Iss. 4
Open Access | Times Cited: 24
Potential renoprotective effect of SGLT2 inhibitors against contrast-induced AKI in diabetic STEMI patients undergoing primary PCI
Barkın Kültürsay, Cemalettin Yılmaz, Barış Güven, et al.
Kardiologia Polska (2024) Vol. 82, Iss. 1, pp. 29-36
Open Access | Times Cited: 12
Barkın Kültürsay, Cemalettin Yılmaz, Barış Güven, et al.
Kardiologia Polska (2024) Vol. 82, Iss. 1, pp. 29-36
Open Access | Times Cited: 12
Utilization Trends of Glucose-Lowering Medications Among Adult Kidney Transplant Recipients with Type 2 Diabetes in the United States
Panupong Hansrivijit, Helen Tesfaye, Deborah J. Wexler, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 651-651
Open Access | Times Cited: 1
Panupong Hansrivijit, Helen Tesfaye, Deborah J. Wexler, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 651-651
Open Access | Times Cited: 1
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
Erythrocytosis and CKD: A Review
Mabel Aoun, Michel Jadoul, Hans‐Joachim Anders
American Journal of Kidney Diseases (2024) Vol. 84, Iss. 4, pp. 495-506
Open Access | Times Cited: 7
Mabel Aoun, Michel Jadoul, Hans‐Joachim Anders
American Journal of Kidney Diseases (2024) Vol. 84, Iss. 4, pp. 495-506
Open Access | Times Cited: 7
Contrast-Induced Acute Kidney Injury in Patients on SGLT2 Inhibitors Undergoing Percutaneous Coronary Interventions: A Propensity-Matched Analysis
Rui Hua, Ning Ding, Hanqing Guo, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 27
Rui Hua, Ning Ding, Hanqing Guo, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 27
Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan
Mu‐Chi Chung, Peir‐Haur Hung, Po‐Jen Hsiao, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e230453-e230453
Open Access | Times Cited: 14
Mu‐Chi Chung, Peir‐Haur Hung, Po‐Jen Hsiao, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e230453-e230453
Open Access | Times Cited: 14
Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study
Johan Mårtensson, Salvatore Lucio Cutuli, E Osawa, et al.
Critical Care (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 13
Johan Mårtensson, Salvatore Lucio Cutuli, E Osawa, et al.
Critical Care (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 13
Kidney Outcomes with Sodium–Glucose Cotransporter-2 Inhibitor Initiation after AKI among Veterans with Diabetic Kidney Disease
Daniel P. Murphy, Julian Wolfson, Scott Reule, et al.
Kidney360 (2024) Vol. 5, Iss. 3, pp. 335-343
Open Access | Times Cited: 5
Daniel P. Murphy, Julian Wolfson, Scott Reule, et al.
Kidney360 (2024) Vol. 5, Iss. 3, pp. 335-343
Open Access | Times Cited: 5
Safety of sodium‐glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
Mauro Rigato, Gian Paolo Fadini, Angelo Avogaro
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 10, pp. 2963-2969
Closed Access | Times Cited: 12
Mauro Rigato, Gian Paolo Fadini, Angelo Avogaro
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 10, pp. 2963-2969
Closed Access | Times Cited: 12
Contrast-Induced Acute Kidney Injury in Patients with Heart Failure on Sodium–Glucose Cotransporter-2 Inhibitors Undergoing Radiocontrast Agent Invasive Procedures: A Propensity-Matched Analysis
Giulia Nardi, Enrico Marchi, Marco Allinovi, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 2041-2041
Open Access | Times Cited: 4
Giulia Nardi, Enrico Marchi, Marco Allinovi, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 2041-2041
Open Access | Times Cited: 4
Updates in chronic kidney disease management: A systematic review
Amina Ammar, Stephanie B. Edwin, Rachel Whitney, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2025)
Open Access
Amina Ammar, Stephanie B. Edwin, Rachel Whitney, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2025)
Open Access
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors
Daniel V. O’Hara, Meg Jardine
Diabetes Obesity and Metabolism (2025)
Open Access
Daniel V. O’Hara, Meg Jardine
Diabetes Obesity and Metabolism (2025)
Open Access
Exploring the complexities of disproportionality analysis in pharmacovigilance: reflections on the READUS-PV guideline and a call to action
Tarek A. Hammad, Melissa Naylor, Dona M Ely, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Tarek A. Hammad, Melissa Naylor, Dona M Ely, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
Anoushka Krishnan, Mythri Shankar, Edgar V. Lerma, et al.
Kidney Medicine (2023) Vol. 5, Iss. 4, pp. 100608-100608
Open Access | Times Cited: 8
Anoushka Krishnan, Mythri Shankar, Edgar V. Lerma, et al.
Kidney Medicine (2023) Vol. 5, Iss. 4, pp. 100608-100608
Open Access | Times Cited: 8
Acute kidney injury events in patients with diabetes using sodium glucose transporter 2 inhibitors: a meta-analysis of cohort studies
Yanjing Shi, Shujie Dong, Yang Xu, et al.
Acta Diabetologica (2024) Vol. 61, Iss. 6, pp. 755-764
Closed Access | Times Cited: 2
Yanjing Shi, Shujie Dong, Yang Xu, et al.
Acta Diabetologica (2024) Vol. 61, Iss. 6, pp. 755-764
Closed Access | Times Cited: 2
Larger Degree of Renal Function Decline in Chronic Kidney Disease Is a Favorable Factor for the Attenuation of eGFR Slope Worsening by SGLT2 Inhibitors: A Retrospective Observational Study
Yoshitaka Miyaoka, Takahito Moriyama, Suguru Saito, et al.
The Nephron journals/Nephron journals (2024) Vol. 148, Iss. 10, pp. 667-677
Closed Access | Times Cited: 2
Yoshitaka Miyaoka, Takahito Moriyama, Suguru Saito, et al.
The Nephron journals/Nephron journals (2024) Vol. 148, Iss. 10, pp. 667-677
Closed Access | Times Cited: 2
Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes
Melissa R. Riester, Andrew R. Zullo, Richa Joshi, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 8, pp. 3403-3417
Closed Access | Times Cited: 2
Melissa R. Riester, Andrew R. Zullo, Richa Joshi, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 8, pp. 3403-3417
Closed Access | Times Cited: 2
Dapagliflozin attenuates AKI to CKD transition in diabetes by activating SIRT3/PGC1-α signaling and alleviating aberrant metabolic reprogramming
Huimin Li, Yao Xia, Hongchu Zha, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 7, pp. 167433-167433
Closed Access | Times Cited: 2
Huimin Li, Yao Xia, Hongchu Zha, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 7, pp. 167433-167433
Closed Access | Times Cited: 2
Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Ja Young Jeon, Dae Jung Kim
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 5, pp. 837-846
Closed Access | Times Cited: 2
Ja Young Jeon, Dae Jung Kim
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 5, pp. 837-846
Closed Access | Times Cited: 2
Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?
Sidar Çöpür, Abdullah Burak Yıldız, Carlo Basile, et al.
Journal of Nephrology (2022) Vol. 36, Iss. 1, pp. 31-43
Closed Access | Times Cited: 10
Sidar Çöpür, Abdullah Burak Yıldız, Carlo Basile, et al.
Journal of Nephrology (2022) Vol. 36, Iss. 1, pp. 31-43
Closed Access | Times Cited: 10
